Theralase Technologies Inc.
TLT.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 619.20K | 587.30K | 718.50K | 769.60K | 684.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 619.20K | 587.30K | 718.50K | 769.60K | 684.50K |
| Cost of Revenue | 216.80K | 222.00K | 320.30K | 339.50K | 319.70K |
| Gross Profit | 402.60K | 365.60K | 398.40K | 430.30K | 364.90K |
| SG&A Expenses | 1.54M | 1.59M | 1.57M | 1.55M | 1.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.30M | 3.57M | 3.86M | 3.87M | 3.91M |
| Operating Income | -2.68M | -2.98M | -3.14M | -3.10M | -3.23M |
| Income Before Tax | -2.66M | -2.94M | -3.10M | -3.06M | -3.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.66 | -2.94 | -3.10 | -3.06 | -3.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.66M | -2.94M | -3.10M | -3.06M | -3.20M |
| EBIT | -2.68M | -2.98M | -3.14M | -3.10M | -3.23M |
| EBITDA | -2.56M | -2.86M | -3.02M | -2.98M | -3.10M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.03B | 1.01B | 1.00B | 987.38M | 970.73M |
| Average Diluted Shares Outstanding | 1.03B | 1.01B | 1.00B | 987.38M | 970.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |